- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01441414
PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma
A PHASE II TRIAL OF PF-04856884 (CVX-060), A SELECTIVE ANGIOPOIETIN-2 (ANG-2) INHIBITOR IN COMBINATION WITH AG-013736 (AXITINIB) IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC RENAL CELL CARCINOMA
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
Brno, Tsjechië, 65653
- Masarykuv onkologicky ustav
-
-
-
-
Arizona
-
Scottsdale, Arizona, Verenigde Staten, 85258
- Pinnacle Oncology Hematology
-
Tucson, Arizona, Verenigde Staten, 85704
- Arizona Oncology Associates, PC - HOPE
-
Tucson, Arizona, Verenigde Staten, 85710
- Arizona Oncology Associates, PC-Hope
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80012
- Rocky Mountain Cancer Centers
-
Boulder, Colorado, Verenigde Staten, 80303
- Rocky Mountain Cancer Centers
-
Centennial, Colorado, Verenigde Staten, 80112
- Rocky Mountain Cancer Centers
-
Colorado Springs, Colorado, Verenigde Staten, 80907
- Rocky Mountain Cancer Centers
-
Colorado Springs, Colorado, Verenigde Staten, 80909
- Rocky Mountain Cancer Centers
-
Denver, Colorado, Verenigde Staten, 80218
- Rocky Mountain Cancer Centers
-
Denver, Colorado, Verenigde Staten, 80220
- Rocky Mountain Cancer Centers
-
Lakewood, Colorado, Verenigde Staten, 80228
- Rocky Mountain Cancer Centers
-
Littleton, Colorado, Verenigde Staten, 80120-4413
- Rocky Mountain Cancer Centers
-
Lone Tree, Colorado, Verenigde Staten, 80124
- Rocky Mountain Cancer Centers
-
Longmont, Colorado, Verenigde Staten, 80501
- Rocky Mountain Cancer Centers
-
Parker, Colorado, Verenigde Staten, 80138
- Rocky Mountain Cancer Centers
-
Pueblo, Colorado, Verenigde Staten, 81008
- Rocky Mountain Cancer Centers
-
Thornton, Colorado, Verenigde Staten, 80260
- Rocky Mountain Cancer Centers
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68114
- Nebraska Methodist Hospital
-
-
Nevada
-
Henderson, Nevada, Verenigde Staten, 89074
- Comprehensive Cancer Centers of Nevada
-
Henderson, Nevada, Verenigde Staten, 89052
- Comprehensive Cancer Centers of Nevada
-
Henderson, Nevada, Verenigde Staten, 89014
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89148
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89128
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89169
- Comprehensive Cancer Centers of Nevada
-
-
North Carolina
-
Durham, North Carolina, Verenigde Staten, 27704
- Regional Cancer Care-Durham
-
-
Texas
-
Tyler, Texas, Verenigde Staten, 75702
- Texas Oncology-Tyler
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98109
- Seattle Cancer Care Alliance
-
Seattle, Washington, Verenigde Staten, 98195
- University of Washington Medical Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Adult male or female patients with histologically or cytologically confirmed renal cell cancer (RCC) with a component of clear cell subtype and evidence of metastasis
- Evidence of unidimensionally measurable disease
- Prior therapy: Part I: Having received 1 to 3 prior systemic regimens for treatment of mRCC
- Part II: Evidence of disease progression following 1 prior regimen administered as 1st line therapy for mRCC. The prior regimen must have contained one of the following: VEGFR2 tyrosine kinase inhibitor (TKI) or other anti VEGF [Vascular Endothelial Growth Factor] compounds, such as bevacizumab
- adequate bone marrow, liver and renal function
Exclusion Criteria:
Part I:
- Intolerant to prior AG 013736 therapy or prior treatment with compounds which contain the core platform antibody as PF 04856884
Part II:
- Prior AG 013736 therapy, more than one systemic first-line regimen for the treatment of mRCC and prior treatment with compounds which contain the core platform antibody as PF 04856884
- major surgery <4 weeks or radiation therapy <2 weeks prior to start of therapy
- clinically significant gastrointestinal abnormalities
- current use or anticipated need for drugs that are known potent CYP3A4 inhibitors and drugs that are known CYP3A4 or CYP1A2 inducers
- history of bleeding diathesis or coagulopathy
- Grade 3 or greater hemorrhage from any cause <4 weeks prior to screening;
- hemoptysis >½ teaspoon of blood per day within 2 weeks prior to screening.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: ARM A
PF-04856884 in combination with AG-013736
|
15 mg/kg/week intravenously [IV] until toxicity or disease progression
5 mg PO BID
|
Actieve vergelijker: ARM B
AG-013736 alone
|
5 mg PO BID
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Number of Participants With Non-serious Adverse Events (AEs) in Part I (Reported in ≥2 of the Participants Overall).
Tijdsspanne: 4 months
|
Incidence and severity of all treatment-emergent AEs (TEAEs) of both all-causality and treatment-related by preferred term (PT) categorized according to Common Terminology Criteria for Adverse Events (CTCAE) grades reported in ≥2 participants overall (CTCAE Grades 3, 4 and 5, combined) for any PT are presented. Participants who are included under all-causality TEAE PT are coded as NA if they appear for the same PT under treatment-related TEAE below. Participants in Part I received PF-04856884 15 mg/kg/week and AG-013736 5 mg twice daily. Following the decision on 06 November 2012 not to continue with Part II of the study, any participant remaining in Part I continued to receive PF-04856884 at a reduced dose of 10 mg/kg/week in combination with AG-013736 (5 mg twice a week) or AG-013736 alone (5 mg twice a week). |
4 months
|
Number of Participants With Serious Adverse Events (SAEs) in Part I
Tijdsspanne: 4 months
|
Incidence and severity of all-causality serious adverse events (SAEs) are presented by PT categorized according to Common Terminology Criteria for Adverse Events (CTCAE) grades.
Participants in Part I received PF-04856884 15 mg/kg/week and AG-013736 5 mg twice daily.
Following the decision on 06 November 2012 not to continue with Part II of the study, any participant remaining in Part I continued to receive PF-04856884 at a reduced dose of 10 mg/kg/week in combination with AG-013736 (5 mg twice a week) or AG-013736 alone (5 mg twice a week).
Participants with treatment-related TEAE are coded as NA if they appear for the same preferred term under all-causality TEAE.
|
4 months
|
Progression Free Survival (PFS) in Adult Participants With Previously Treated Metastatic Renal Cell Cancer (mRCC) in Part II
Tijdsspanne: 3 years
|
PFS is defined as the time (in days) from date of randomization to first documentation of investigator assessed tumor progression or death, whichever comes first.
Progression free survival was to be calculated as (first event date - the date of randomization +1).
|
3 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Number of Participants With Non-serious AEs and SAEs
Tijdsspanne: 3 years
|
Incidence and severity of all-causality AEs and SAEs to be presented by PT categorized according to Common Terminology Criteria for Adverse Events (CTCAE) grades.
Participants in Part I received PF-04856884 15 mg/kg/week and AG-013736 5 mg twice daily.
Following the decision on 06 November 2012 not to continue with Part II of the study, any participant remaining in Part I continued to receive PF-04856884 at a reduced dose of 10 mg/kg/week in combination with AG-013736 (5 mg twice a week) or AG-013736 alone (5 mg twice a week).
|
3 years
|
Overall Response Rate (ORR) in Metastatic Renal Cell Cancer (mRCC) Patients Treated With PF-04856884 in Combination With AG-013736 vs. AG-013736 Alone.
Tijdsspanne: 4 months
|
ORR is defined as the proportion of participants with confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST), relative to all randomized participants as defined in the FA Set.
Confirmed responses are those that persist on repeat imaging study ≥ 4 weeks after initial documentation of response.
Participants who do not have on-study radiographic tumor evaluation or who die, progress, or drop out for any reason prior to reaching a CR or PR will be counted as non-responders (NR) in the assessment of ORR.
|
4 months
|
Duration of Response (DR) in Metastatic Renal Cell Cancer (mRCC) Patients Treated With PF-04856884 in Combination With AG-013736 vs. AG-013736 Alone
Tijdsspanne: 3 years
|
DR is defined as the time from the first documentation of objective tumor response (CR or PR) that is subsequently confirmed to the first documentation of tumor progression or to death due to cancer.
Duration of tumor response was to be calculated as (the end date for DR - first CR or PR that is subsequently confirmed +1).
|
3 years
|
Tmax (Time When Maximum Serum PF-04856884 Concentration Was Reached)
Tijdsspanne: Pre-dose, 1, 2, 4, 6, 8, 192, 360, 361, 362, 365, 367 hours post dose and end of treatment
|
Pharmacokinetic parameter, Tmax (Time when maximum serum PF-04856884 concentration was reached) was done using non-compartmental methods.
|
Pre-dose, 1, 2, 4, 6, 8, 192, 360, 361, 362, 365, 367 hours post dose and end of treatment
|
Cmax (Observed Peak Serum PF-04856884 Concentration)
Tijdsspanne: Pre-dose, 1, 2, 4, 6, 8, 192, 360, 361, 362, 365, 367 hours post dose and end of treatment
|
Pharmacokinetic parameter Cmax (observed peak PF-04856884 serum concentration) was estimated using noncompartmental methods.
|
Pre-dose, 1, 2, 4, 6, 8, 192, 360, 361, 362, 365, 367 hours post dose and end of treatment
|
Cmin (Trough PF-04856884 Serum Concentration)
Tijdsspanne: Pre-dose, 1, 2, 4, 6, 8, 192, 360, 361, 362, 365, 367 hours post dose and end of treatment
|
Pharmacokinetic parameter Cmin (trough PF-04856884 serum concentration) was estimated using noncompartmental methods.
|
Pre-dose, 1, 2, 4, 6, 8, 192, 360, 361, 362, 365, 367 hours post dose and end of treatment
|
Number of Anti-drug Antibodies (ADA) Samples Confirmed Positive
Tijdsspanne: 0 and 360 hours post dose and end of study
|
Detection of neutralizing anti-PF-04856884 antibodies was based on the ability of anti-PF-04856884 neutralizing antibodies to bind to Tag-PF-04856884.
|
0 and 360 hours post dose and end of study
|
Progression Free Survival (PFS) in Adult Participants With Previously Treated Metastatic Renal Cell Cancer (mRCC) as Measured by an Independent Radiological Assessment
Tijdsspanne: 3 years
|
PFS is defined as the time (in days) from date of randomization to first documentation of investigator assessed tumor progression or death, whichever comes first.
PFS was to be calculated as (first event date - the date of randomization +1).
|
3 years
|
Overall Survival (OS) at 2 Years
Tijdsspanne: 5 years
|
OS is defined as the time from the first dose date to date of death.
For participants not expiring, their survival times will be censored at the last date they are known to be alive, or 2 year whichever is earlier.
The 2-year OS rate will be estimated from a time-to event analysis of OS.
|
5 years
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per histologisch type
- Neoplasmata
- Urologische neoplasmata
- Urogenitale neoplasmata
- Neoplasmata per site
- Nier Ziekten
- Urologische ziekten
- Adenocarcinoom
- Neoplasmata, glandulair en epitheel
- Nierneoplasmata
- Carcinoom, niercel
- Carcinoom
- Moleculaire mechanismen van farmacologische werking
- Enzymremmers
- Antineoplastische middelen
- Proteïnekinaseremmers
- Axitinib
Andere studie-ID-nummers
- B1131004
- 2011-002190-33 (EudraCT-nummer)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op PF-04856884
-
PfizerVoltooid
-
University of FloridaVoltooidGastro-intestinale symptomen | Ontlasting Frequentie | Gastro-intestinale transittijdVerenigde Staten
-
PfizerVoltooid
-
PfizerVoltooid
-
PfizerVoltooidGezondVerenigde Staten
-
PfizerWervingAtopische dermatitisVerenigde Staten, Canada